zoetis stock quote Overview and Ratings

Zoetis stock quote is a popular choice among investors, with a market capitalization of over $150 billion. This is a significant milestone for the company, which was spun off from Pfizer in 2013.

Zoetis has a strong track record of delivering consistent returns to shareholders, with a 5-year average annual return of 15%. This is a testament to the company's successful business model and commitment to innovation.

The company's stock is listed on the New York Stock Exchange (NYSE) under the ticker symbol ZTS. As of the latest available data, the stock has a beta of 0.85, indicating that it tends to move in tandem with the overall market.

Zoetis has received a number of ratings from top brokerage firms, including a "buy" rating from Goldman Sachs and a "hold" rating from Morgan Stanley.

Zoetis has shown impressive growth with a 17.55% CAGR since its IPO, outperforming the S&P 500.

The company has benefited from increasing global pet ownership and spending, which is expected to drive growth in the pet industry.

The pet industry is growing fast and could reach a global market size of half a trillion dollars by 2032.

Investors should take note of Zoetis' strong track record and the potential for continued growth in the pet industry.

Zoetis stock has seen significant growth in recent years, with its market value increasing by over 50% since its IPO in 2013.

The company's strong financial performance is a key driver of this growth, with revenue increasing from $2.3 billion in 2013 to $6.4 billion in 2020.

Zoetis has a diverse portfolio of products, with a focus on animal health and a presence in over 40 countries.

Its innovative products, such as the Capstar flea control treatment, have been well-received by veterinarians and pet owners alike.

The company's commitment to research and development is evident in its investment of over $500 million in R&D each year.

This investment has led to the development of new products and technologies that are helping to improve animal health and wellbeing.

Zoetis has a strong track record of delivering profitable growth, with a compound annual growth rate (CAGR) of over 15% since its IPO.

Zoetis Inc. is a company that specializes in animal health products and services. They operate globally and offer a wide range of products across different species.

The company's product portfolio includes medicines, vaccines, diagnostic products, and services for livestock such as cattle, swine, poultry, fish, and sheep. They also cater to companion animals like dogs, cats, and horses.

Zoetis offers various types of products, including parasiticides, vaccines, dermatology products, anti-infectives, and medicated feed additives.

Zoetis Inc. is a company that's been around for a while, with its first dividend payment recorded in 2013.

The company has a strong presence in the animal health industry, with a focus on livestock and companion animals. They offer a range of products, including parasiticides, vaccines, and medicated feed additives.

One of the notable things about Zoetis is its growing revenue, with a compound annual growth rate (CAGR) of 4% or more across multiple segments.

Here's a breakdown of Zoetis' dividend payments over the years:

As you can see, the dividend payment has been increasing over the years, with a significant jump in 2022 and 2023.

Zoetis has a strong osteoarthritis pain franchise, with products like LIBRELA and STRIDE.

The company's osteoarthritis drugs have performed well, contributing to Zoetis' overall success.

A 'Buy' rating has been assigned to Zoetis, with a one-year target price of $210 per share, due to the company's strong product performance and strategic divestitures.

Zoetis' focus on osteoarthritis pain management has led to significant growth and opportunities for the company.

Zoetis is active in multiple segments that are all expected to grow at a CAGR of 4% or more. The company has a strong presence in the animal health industry.

The segments Zoetis is involved in are expected to see significant growth, with a combined compound annual growth rate (CAGR) of 4% or more. This suggests a promising outlook for the company's future performance.

Zoetis has growing revenues, which is a clear indicator of the company's financial health and success. This growth is a result of the company's focus on the animal health industry.

A strong balance sheet is another key aspect of Zoetis's financial health, providing a solid foundation for the company's future growth and development. This balance sheet is a testament to the company's effective management and financial planning.

Zoetis also boasts a high free cash flow (FCF) margin, which is a measure of a company's ability to generate cash from its operations. This high FCF margin indicates that Zoetis is generating a significant amount of cash from its business, which can be used to invest in growth opportunities or pay off debt.

Analysts are overwhelmingly bullish on Zoetis stock, with an average rating of "Strong Buy" from 8 stock analysts.

This means that analysts believe Zoetis stock is likely to perform very well in the near future and significantly outperform the market.

The 12-month stock price forecast is $215.38, which is an increase of 26.38% from the latest price.

Here's a summary of the analyst ratings:

Analyst Ratings play a crucial role in determining the performance of a stock. The average analyst rating for Zoetis stock from 8 stock analysts is "Strong Buy".

Analysts believe this stock is likely to perform very well in the near future and significantly outperform the market. This is evident from the consistent "Maintained Buy" ratings from various analysts.

The 12-month stock price forecast is $215.38, which is an increase of 26.38% from the latest price. This forecast is based on the average rating from 8 analysts.

Here is a breakdown of the analyst ratings:

The consistent "Maintained Buy" ratings from various analysts suggest that they are confident in the stock's performance.

The Piper Sandler 36th Annual Healthcare Conference is a significant event where companies like Zoetis Inc. share their updates and insights.

Zoetis Inc. participated in the conference, with Wetteny Joseph, their Chief Financial Officer, representing the company.

The conference call took place on December 3, 2024, at 11:30 AM ET.